.Pharmacolibrary.Drugs.ATC.J.J05AR13 .Pharmacolibrary.Drugs.ATC.J.J05AR13| name: | LamivudineAbacavirAndDolutegravir | |
| ATC code: | J05AR13 | route: | oral |
| compartments: | 1 | |
| dosage: | 600 | mg |
| volume of distribution: | 111 | L |
| clearance: | 15 | L/h |
| other parameters in model implementation | ||
The fixed-dose combination of lamivudine, abacavir, and dolutegravir is an oral antiretroviral medication used for the treatment of HIV-1 infection in adults and adolescents. It is currently approved and widely used as a complete regimen in HIV management. Lamivudine and abacavir are both nucleoside reverse transcriptase inhibitors (NRTIs), while dolutegravir is an integrase strand transfer inhibitor (INSTI).
Pharmacokinetic parameters reported for healthy adult volunteers after oral administration of the fixed-dose combination (Triumeq).